BG Medicine Announces Decision by American Medical Association and Centers for Medicare and Medicaid Services on Analyte

BG Medicine Announces Decision by American Medical Association and Centers for
Medicare and Medicaid Services on Analyte-Specific CPT(R) Code and
Reimbursement for BGM Galectin-3(R) Test

WALTHAM, Mass., Nov. 7, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a company focused on the development and commercialization of
novel cardiovascular diagnostics, announced today that the Centers for
Medicare and Medicaid Services (CMS), in the Final Determination for the
Medicare Clinical Laboratory Fee Schedule for 2013, assigned a payment rate
for the BGM Galectin-3® test under new analyte-specific Current Procedural
Terminology (CPT®) code 82777 effective January 1, 2013. The CMS Final
Determination decision comes in response to BG Medicine's request for an
analyte-specific CPT code and recommendation that CMS assign a higher payment
rate for the new code. CMS did not accept the recommendation for a higher
payment rate, however, the payment rate will be crosswalked to the code under
which the test is currently paid. The BGM Galectin-3 test is a novel test,
which is cleared by the U.S. Food and Drug Administration as an aid in
assessing the prognosis of patients with chronic heart failure.

"The BGM Galectin-3 test represents a true and significant advancement for
chronic heart failure patients and a critical tool for the physicians who make
decisions about their medical care. We will pursue an increased Medicare
reimbursement rate for this test for 2014 that, we believe, will more
appropriately reflect the value of this important diagnostic test," said Eric
Bouvier, president and chief executive officer of BG Medicine. "As we work
toward that goal, we're accelerating our efforts to expand commercialization
of the BGM Galectin-3 test, supported by the reimbursement already in place."

Studies have shown that 30 – 50% of chronic heart failure patients suffer from
an inherently progressive form of the disease that is mediated by the
galectin-3 protein. Due to underlying fibrosis that is believed to be
associated with galectin-3, patients with this form of heart failure are more
prone to rapidly lose cardiac function and are at an increased risk for
hospitalization, re-hospitalization and death.

Even with optimal care, today nearly a quarter of all Medicare heart failure
patients are readmitted to the hospital within 30 days, making heart failure a
major driver of hospital readmission rates, far ahead of myocardial infarction
and pneumonia. Because heart failure patients with elevated galectin-3 are
two-to-three times more likely to be readmitted to the hospital within 30 days
of discharge, galectin-3 testing is a potentially valuable and cost-effective
tool in a hospital's strategy to reduce unplanned readmissions. We believe
that identifying those patients at greater risk with galectin-3 testing will
enable hospitals and physicians to better direct their intervention strategies
and resources to those who need them most, potentially providing a way to
improve outcomes while also controlling costs and avoiding penalties imposed
by Medicare relating to hospital readmissions.

The BGM Galectin-3 test is the first blood test that can detect elevated
levels of the galectin-3 protein, helping physicians better understand the
prognosis of patients diagnosed with chronic heart failure as well as what
treatments may work best. Galectin-3 testing is indicated for use in patients
previously diagnosed with chronic heart failure and cannot be used to diagnose
heart failure.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the
discovery, development and commercialization of novel cardiovascular
diagnostics to address significant unmet medical needs, improve patient
outcomes and contain healthcare costs. The Company's first commercialized
product, the BGM Galectin-3® test for use in patients with heart failure, is
available in the United States and Europe.BG Medicine is also developing the
CardioSCORE TM test, a blood test designed to identify individuals at high
risk for near-term major cardiovascular events, such as heart attack and
stroke.For additional information about BG Medicine, heart failure and
galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

CPT is a registered trademark of the American Medical Association.

The BG Medicine Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. Forward-looking statements in this
news release address our ability to expand commercialization of galectin-3
testing; our belief regarding the potential impact of the CMS decision on
future sales of our galectin-3 test; our ability to obtain a higher
reimbursement rate for our galectin-3 test; our understanding that heart
failure patients with elevated galectin-3 are two-to-three times more likely
to be readmitted to the hospital within 30 days of discharge than other heart
failure patients; our belief that identifying these high-risk patients through
galectin-3 testing is a potentially valuable and cost-effective tool in
reducing unplanned readmissions; our belief that identifying patients at
greater risk with galectin-3 testing will enable hospitals and physicians to
more efficiently and cost-effectively direct intervention strategies and
resources; our belief that increased usage of galectin-3 testing by the
healthcare system may improve health outcomes and reduce healthcare costs.
Forward-looking statements are based on management's current expectations and
involve inherent risks and uncertainties which could cause actual results to
differ materially from those in the forward-looking statements, as a result of
various factors including those risks and uncertainties described in the Risk
Factors and in Management's Discussion and Analysis of Financial Condition and
Results of Operations sections of our recent filings with the Securities and
Exchange Commission, including our most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We caution readers
not to place undue reliance upon any such forward-looking statements, which
speak only as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to publicly release
any updates or revisions to any forward-looking statement contained herein (or
elsewhere) to reflect any change in our expectations with regard thereto or
any change in events, conditions or circumstances on which any such statement
is based.

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         (781) 434-0210

BG Medicine Inc. logo